MiMedx Group, Inc.
NASDAQ:MDXGBiotechnology
+$0.08 today
- Market cap
- $464.04M
- Beta
- 1.46
- P/E (TTM)
- 17.8
- EPS (TTM)
- $0.21
Volume 1.51M
Average 1.55M
MDXG Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MiMedx Group, Inc.NASDAQ: MDXG
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.62M fell 49.5% year over year, behind the +94.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +54.4% a year.
Context
- Depreciation & amortization amounted to 3.6% of revenue in FY2025, up 1.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -49.5% toward the trailing-twelve-month pace of +94.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 14.88M USD
- Year-over-year change
- +146.3%
- 4-year CAGR
- +30.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.88M | +146.3% |
| FY2024 | 2024-12-31 | 6.04M | +76.3% |
| FY2023 | 2023-12-31 | 3.43M | -15.3% |
| FY2022 | 2022-12-31 | 4.05M | -21.9% |
| FY2021 | 2021-12-31 | 5.18M | — |
Depreciation & Amortization vs competitors
How MDXG compares with its peers on the latest reported figures
- MDXG's LTM Mar 2026 depreciation & amortization of $16.5M is the 3rd largest of the 8 companies compared; the peer median is $2.15M.
- Its year-over-year change of +94.2% is the 2nd highest of 8, against a peer median of +27.6%.
- Depreciation & amortization amounts to 4.2% of revenue for MDXG, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.95M | +45.2% | +35.9% | 6.0% | |
| LTM Mar 2026 | $28.02M | +456.0% | +129.2% | 26.1% | |
| LTM Mar 2026 | $16.5M | +94.2% | +54.4% | 4.2% | |
| LTM Dec 2025 | $7.3M | -7.9% | -8.2% | 27.5% | |
| LTM Mar 2026 | $2.15M | +48.5% | +53.1% | 3.0% | |
| LTM Mar 2026 | $1.88M | +27.6% | +10.4% | 13.0% | |
| LTM Mar 2026 | $723K | +20.9% | -1.3% | 4.9% | |
| LTM Jun 2026 | $384.08K | -31.7% | +16.1% | — | |
| Peer median (excluding MDXG) | $2.15M | +27.6% | +16.1% | 9.5% | |
Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.3M) | (19.95M) | 67.44M | 42M | 48.58M |
| Depreciation & Amortization | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M |
| Deferred Income Tax | 0 | 0 | (37.8M) | 12.47M | 8.71M |
| Stock-Based Compensation | 14.16M | 11.33M | 16.96M | 16.93M | 16.4M |
| Change in Working Capital | (19.35M) | (8.01M) | (18.42M) | (5.43M) | (22.98M) |
| Accounts Receivables | (10.62M) | (5.94M) | (12.24M) | (2.55M) | (26.39M) |
| Inventory | (1.41M) | (1.79M) | (7.84M) | (2.36M) | (1.53M) |
| Accounts Payables | (159K) | 839K | 783K | (1.41M) | 2.12M |
| Other Working Capital | (7.17M) | (1.12M) | 876K | 885K | 2.83M |
| Other Non-Cash Items | 10.33M | 6.03M | (4.83M) | (5.81M) | 8.42M |
| Operating Cash Flow | (1.98M) | (17.89M) | 26.78M | 66.2M | 74M |
| Capital Expenditures | (3.22M) | (1.51M) | (1.99M) | (1.68M) | (1.03M) |
| Acquisitions (Net) | 0 | 24K | 0 | (7.86M) | (3.76M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (177K) | (1.15M) | (168K) | (38K) | 0 |
| Investing Cash Flow | (3.4M) | (2.66M) | (2.16M) | (9.58M) | (6.89M) |
| Debt Repayment | (38K) | (41K) | (52K) | (31.72M) | (1M) |
| Common Stock Issued | 0 | 651K | 997K | 0 | 0 |
| Common Stock Repurchased | (4.75M) | (1.19M) | (9.52M) | (2.64M) | (3.12M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.44M | (41K) | 9.46M | 159K | (1.29M) |
| Financing Cash Flow | (3.35M) | (580K) | (8.57M) | (34.2M) | (5.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.73M) | (21.13M) | 16.05M | 22.42M | 61.71M |
| Free Cash Flow | (5.2M) | (19.41M) | 24.79M | 64.52M | 72.97M |
MiMedx Group, Inc.
NASDAQ:MDXG
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.